Cardiovasculaire Geneeskunde.nl

LDL and cardiovascular disease: Latest insights

Slides (presentatie) - Dec. 7, 2011

LDL and cardiovascular disease: Latest insights


Deze presentatie is gehouden door:
Prof. dr. John Kastelein, internist
Academisch Medisch Centrum, Amsterdam
 
tijdens het WCN congres op 24 november 2011


Bekijk of download de presentatie

klik voor bekijken op onderstaande afbeeldingen
 


LDL and cardiovascular disease: Latest insights

New Approaches to LDL Reduction and HDL Increase

Ezetimibe strongly increases TICE

Prospective Clinical Events Trials Examining the Effects of Statins in ESRD Patients

Relationship Between GFR and CVD Outcomes

4D Study

4D Study

AURORA Study

AURORA Study Design

AURORA Study: Cumulative Incidence of Primary Endpoint

The results of the Study of Heart and Renal Protection (SHARP)

SHARP: Rationale

SHARP: Eligibility

SHARP: Assessment of LDL-lowering

SHARP: Baseline characteristics

SHARP: Compliance and LDL-C reduction at study midpoint

SHARP: Baseline paper and Data Analysis Plan

SHARP: Main outcomes

SHARP: Major Atherosclerotic Events

CTT: Effects on Major Atherosclerotic Events

CTT: Effects on Major Atherosclerotic Events

SHARP: Major Vascular Events

SHARP: Effects in subgroups

SHARP: Major Atherosclerotic Events by renal status at randomization

SHARP: Cause-specific mortality

SHARP: Renal outcomes

SHARP: Cancer incidence

SHARP: Safety

SHARP: Conclusions

The Inhibition of Cholesterol Ester Transfer Protein

CETP Levels and CAD risk: The EPIC – Norfolk study

Scientific Case for Developing the CETP inhibitor Anacetrapib

Anacetrapib Dose Ranging Study

Effect of HDL from Anacetrapib-treated Patients on Cholesterol Efflux from Human Macrophages

Effect of Torcetrapib and Anacetrapib on Blood Pressure in Rhesus Monkeys

The Effect of Torcetrapib and Anacetrapib on Aldosterone Secretion from Primary Rat Adrenocortical Cells

Effects on LDL-C and HDL-C

Conclusion

Future

Nicotinic Acid Treatment of Dyslipidemia and Atherosclerosis

Niacin Raises HDL-C and Decreases LDL-C, TG, and Lp(a) in a Dose-Dependent Manner

Effectiveness of 2 g vs 1 g of ER Niacin

Most Patients on ER Niacin Therapy Do Not Reach a 2-g Dose

Niacin Flushing Pathway: Two Separate Steps and Sites of Action

Lipid/Flushing Study: Lower Incidence of Moderate or Greater Flushing vs ER Niacin

Factorial Study: Lipid Efficacy

HPS2-THRIVE

Conclusion

Deze inhoud is bedoeld voor medische professionals. Om dit te bekijken is registratie noodzakelijk. Registreer gratis voor onbeperkte toegang tot ons educatief materiaal.

Deel deze pagina met collega's en vrienden: